Cipla USA Recalls Over 400 Cartons of Nilotinib Cancer Drug in US

Cipla USA, a subsidiary of Indian drugmaker Cipla, is voluntarily recalling over 400 cartons of its generic anti-cancer drug Nilotinib Capsules in 150 mg and 200 mg strengths due to manufacturing issues related to failed tablet capsule specifications. The recall, classified as Class III by the USFDA, indicates no expected adverse health consequences. Indian pharmaceutical companies supply a significant portion of US prescriptions, with India hosting the highest number of USFDA-compliant plants outside the US.